NN-3201

N/A

Report date: 2025/03/13 15:11:06

Base Information

Drug NameNN-3201
Drug Alias NameNN-3201
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Stem cell growth factor receptorTubulin inhibitorsApoptosis stimulants +[5] 
TargetsStem cell growth factor receptorTubulin
Therapy Area/IndicationsUveal melanomaSmall Cell Lung CarcinomaCarcinoma, Renal Cell +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovelty Nobility Inc
China Registration ClassN/A

Develop Information

Active CompaniesNovelty Nobility Inc
Inactive CompaniesN/A
Active IndicationsUveal melanomaSmall Cell Lung CarcinomaCarcinoma, Renal Cell +[6] 
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A